SAMANTHA FARNUM: Open Payments
NPI 1437518552 · FAIRMONT, MN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$255 in 16 payments from 11 companies in 2025. Trend: 2023 $237 · 2024 $276 · 2025 $255
Food & beverage: $255
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Phadia US Inc. | 2 | $29 |
| ACADIA Pharmaceuticals Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| ABBVIE INC. | 1 | $14 |
| Amgen Inc. | 1 | $14 |
Products named: AUSTEDO XR, CAPLYTA, NEXLETOL, KEVEYIS, ImmunoCAP, NUPLAZID, ZEPBOUND, TRINTELLIX.
Industry payments across MN — which companies pay providers there.
